SEC Form 4 · accession 0000899243-18-028518
T2 Biosystems, Inc. · TTOO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Stanley Lapidus
Director
Period of report
Nov 6, 2018
Accepted (ET)
Nov 8, 2018 · 2:05 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001492674
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 6, 2018 | M | 27,058 | $1.16 | A | 59,058 | D | |
| Common StockF1 | Nov 6, 2018 | S | 6,048 | $5.29 | D | 53,010 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $1.16 | Nov 6, 2018 | M | 27,058 | D | Aug 20, 2012 | Jan 16, 2019 | Common Stock | 27,058 | 0 | D |
Explanation of responses
- F1The price reported is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $5.27 to $5.33. The reporting person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.